The severe complications of dengue virus infections, hemorrhagic manifestations and shock, are more commonly observed during secondary dengue virus infections than during primary infections. It has been speculated that these complications are mediated by cross-reactive host-immune responses. We have begun to analyze human T cell responses to dengue antigens in vitro to explain the possible role of T lymphocytes in the pathogenesis of these complications. Dengue antigens induce proliferative responses of PBMC from dengue antibody-positive donors, but do not induce specific proliferative responses of PBMC from dengue antibody-negative donors. IFNy is detected in the culture fluids of dengue-immune PBMC stimulated with dengue antigens. The cells that proliferate in the dengue antigen-stimulated bulk cultures have CD3+, CD4+, CD8-, CD16-, and CD20-phenotypes. Dengue-specific T cell lines were established using limiting dilution techniques. They have CD3+, CD4+, and CD8-phenotypes, and produce IFNy in response to dengue antigens. Culture fluids from dengue-immune PBMC stimulated with dengue antigens, which contain IFN'y, augment dengue virus infection of human monocytes by dengue virus-antibody complexes.
Introduction
The severe complications of dengue virus infections, hemorrhagic manifestations and shock, are much more commonly observed during secondary infections with a heterologous serotype of dengue virus than during primary infections (1) . It has been speculated that dengue hemorrhagic fever (DHF)' and dengue shock syndrome (DSS) may be mediated by crossreactive host-immune responses (2). Halstead et al. have reported that anti-dengue antibodies at subneutralizing concentrations enhance dengue virus infection of Fc receptor-positive cells (3, 4) . They have hypothesized that the number ofdengue virus-infected monocytes increases in secondary infections because of the presence of anti-dengue antibodies and this results in DHF and DSS (1) .
We recently reported that IFNy augments dengue virus infection of human monocytes and a human monocytic cell line, U937 (5) . This augmentation required the presence of anti-dengue antibody, and the augmentation of infection was significantly correlated with the increased expression of Fcy receptors induced by IFNy. We reported earlier that PBMC from influenza-immune donors produce high titers of IFNy when stimulated with influenza virus in vitro (6) . These two observations stimulated us to consider further the role of dengue-specific T cells in the pathogenesis of dengue virus infections. In this paper we describe human T cell proliferative responses and IFNy production in vitro induced by dengue antigens. PBMC from dengue antibody-positive donors proliferate and produce IFNy after stimulation with dengue antigens. The responding cells are T cells (CD3+) with CD4 (helper/inducer) phenotype. The IFNy produced augments dengue virus infection of human monocytes by dengue virusantibody complexes.
Methods
Human PBMC. Peripheral blood specimens were obtained from healthy adult Thai Red Cross blood bank donors in Bangkok, Thailand, and from two American donors who were known to have been infected with dengue virus. The sera ofthese donors contained hemagglutination-inhibiting (HAI) antibodies to dengue viruses (mean HAI titers; 1:49 to dengue 1, 1:58 to dengue 2, 1:118 to dengue 3, 1:272 to dengue 4). Most of the Thai people have antibodies to dengue viruses by age 10 (7). The two American donors had previously been immunized with yellow fever vaccine. Both were known to have been infected with dengue 3 virus, strain CH53489, by virus isolation from blood and they developed antibody responses to dengue virus. PBMC were also obtained from healthy blood bank donors from Massachusetts who did not have detectable levels of antibodies to dengue virus determined using a plaque reduction neutralization test that has been described earlier (8) . We define dengue-immune donors as dengue antibody-positive donors, and non-immune donors as dengue anti-body-negative donors. PBMC were separated by Ficoll-Hypaque density gradient centrifugation methods (9) . Cells were resuspended at the concentration of I X 107/ml in RPMI 1640 medium containing 10% FCS (Gibco Laboratories, Grand Island, NY) and 10% DMSO (Fisher Scientific Co., Springfield, NJ) and were cryopreserved until use (8) .
Viruses. The dengue virus strains used were type 1, the Hawaii strain; type 2, the New Guinea C strain; type 3, the CH53489 strain, and type 4, the 814669 strain. Dengue virus types 1 and 2 were supplied by Dr. Walter E. Brandt, and type 4 was supplied by Mr. Jack McCown ofthe Walter Reed Army Institute ofResearch. Dengue virus type 3 was supplied by one of the authors (Dr. Bruce Innis).
Preparation of dengue antigens. Dengue antigens were prepared using dengue virus-infected Vero cells as previously reported for measles virus (10) . Vero cells were infected with dengue virus at an approximate multiplicity of infection of 1 plaque-forming unit/cell, and cultured in MEM containing 2% FCS. When 50% of the monolayer developed cytopathic effects, the cells were removed using cell scrapers (Costar Corp., Cambridge, MA), washed three times with PBS at 40C, treated with 0.025% glutaraldehyde (Sigma Chemical Co., St. Louis, MO) in PBS for 15 min at 4VC, washed again three times with PBS, and resuspended in RPMI 1640. They were then sonicated with a sonic dismembrator (Fisher Scientific Co., Pittsburgh, PA), and centrifuged at 2,500 rpm for 10 min. The supernatant fluids were collected and used as dengue antigens. Control antigens were prepared in a similar manner using uninfected Vero cells. Phenotypic analysis. Anti-Leu2 (CD8) antibody reacts with suppressor/cytotoxic T cells (1 1). Anti-Leu3 (CD4) antibody reacts with helper/inducer T cells (1 1). Anti-Leu4 (CD3) antibody reacts with pan T cells (12) . Anti-Leul 1 (CD 16) antibody reacts with natural killer cells and neutrophils (13) . Anti-B 1 (CD20) antibody reacts with B cells (14) . Anti-Leu2, Leu3, Leu4, and Leul 1 antibodies were purchased from Becton-Dickinson & Co. (Mountain View, CA). Anti-B 1 antibody was purchased from Coulter Electronics, Inc. (Hialeah, FL). Cell lines and clones were stained with MAb conjugated with fluoresceinisothiocyanate by direct immunofluorescence methods as described earlier (15) . They were observed under a fluorescence microscope (Carl Zeiss, Inc., Oberkochen, FRG).
Immunoassays for IFN. Sandwich-type ELISA for the estimation of IFN The detection limit of the IFNy-specific ELISA was 0.5 IU/ml.
For IFNa determination, the ELISA was carried out in a manner similar to that described above for IFN'y-specific ELISA except that the rabbit and mouse antibodies against IFNy were replaced by IFNa-specific antibodies (18, 19) . This IFNa-specific ELISA was calibrated with the first international reference preparation for human leukocyte IFN 69/19, 5,000 IU per ampoule, and the detection limit of the assay was 10 IU/ml in this version.
Effect ofIFNproduced by PBMC stimulated by dengue antigens on dengue virus infection. Supernatant fluids from cultures of PBMC of dengue-immune donors that had been stimulated with dengue antigen as described above, were diluted to contain 3 U/ml of IFNy, and culture fluids ofthe same PBMC exposed to control antigen, which did not contain detectable levels of IFN-y, were diluted similarly. These fluids were then used to pretreat human monocytes for 24 h before addition of dengue virus-antibody complexes at multiplicity of infec- (Table II) . IFNa was not detected in the culture fluid of PBMC after stimulation with dengue or control antigen (data not presented). The culture fluids of PBMC from antibody-negative donors stimulated with dengue antigens did not contain significant titers of IFNs. These results indicate that dengue-immune PBMC produce high titers of IFNy after stimulation with dengue antigens, but do not produce IFNa. IFNy was detected at low titers in the culture fluids of PBMC from some donors cultured without antigens. It has been reported that PBMC from some normal adults produce IFNy during in vitro culture without the addition of specific antigens (20) .
Characterization ofthe lymphocytes responding to dengue antigens. We cultured the proliferating lymphocytes with 'y-irradiated autologous PBMC in the presence of dengue antigens and IL 2 for 7 or 14 d, after the original 7 d of bulk culture stimulation, to characterize the lymphocytes that responded to dengue antigen. Phenotypic analyses showed that the proliferating cells were predominantly CD3+, CD4+, CD8-, CD16-, and CD20- (Table III) . Therefore, the proliferating cells are T cells with the helper/inducer phenotype. They produced IFNy after stimulation with dengue antigens, but not after stimulation with control antigen (Table IV) .
Analysis ofresponding cells by establishing dengue-specific T cell lines. We further characterized the T cells that respond to dengue antigen by establishing dengue-specific T cell lines by a limiting dilution method using lymphocytes from one American donor who was known to have been infected with dengue 3 virus. 14 T cell lines, which responded to dengue 3 antigen but not to control antigen, were established. Three of these lines were further expanded. The JK3 and JKlO lines were established from wells containing 10 blast cells. The JK1 5 line was established from a well containing 30 blast cells. The cloning efficiency was 23% with 10 cells/well, and 56% with 30 cells/well, respectively. All three lines had CD3+, CD4+, and CD8-phenotypes (data not presented), and responded to dengue 3 antigen, but did not respond to control antigen (Table V) . They produced IFNy after stimulation with dengue 3 antigen but did not produce IFN-y after stimulation with control antigen (Table V) . They did not produce significant titers of IFNa. Augmentation of dengue virus infection of human monocytes by IFNy produced by PBMC in response to dengue antigen. We tried to determine whether the culture fluids of PBMC stimulated with dengue antigen could augment dengue virus infection of human monocytes. We recently reported that recombinant human IFNy augmented dengue virus infection of human monocytes and monocytic cells in the presence of anti-dengue antibody (5) . Culture fluids were obtained from dengue-immune PBMC after stimulation with dengue antigen, and they were then diluted to contain 3 U/ml ofIFNy. Culture fluids of the same dengue-immune PBMC that had been exposed to control antigen were similarly diluted. Human monocytes were exposed to these culture fluids for 24 h. They were then washed and infected with dengue virus-antibody complexes. A similar percent of the monocytes that were cultured without the addition of culture fluids from PBMC and that were treated with the diluted culture fluid from dengue-immune PBMC that had been exposed to control antigen became infected and expressed dengue antigens; however, increased number of the monocytes treated with diluted culture fluids from dengue-immune PBMC that had been exposed to dengue antigen and contained 3 U/ml of IFN-y had dengue viral antigens (Table VI, (32) . Recently, it has been reported that immunization of mice with dengue 2 virus NS1 protein provided significant protection against lethal challenge with dengue 2 virus (33) . Identification of the epitopes or dengue antigens that are recognized by T cells and may have a role in protection or in the pathogenesis of DHF and DSS is an important area for research.
The severe complications of dengue virus infections, DHF and DSS, are much more commonly observed during secondary dengue infections than during primary infections (1, 2, 34 ).
However, a small percentage of DHF/DSS cases is observed during primary infections and most of these are primary infections of infants between 6 and 12 mo of age born to dengue antibody-positive mothers (1, 2). Kliks et al. recently reported that there is a correlation between the level of maternal dengue antibodies and occurrence of DHF/DSS of the infants during the first year of age (35) . Therefore, although we speculate that there is a role for dengue-specific T cells in the pathogenesis of DHF/DSS, which is much more commonly observed during secondary infections, such specific T cell memory responses do not explain these complications when they occur, although much less frequently, during primary infections.
In this paper, we demonstrated that dengue-specific CD4+ T cells produce high titers of IFNy. It has been reported that antigen-specific T cells produce IFNy after stimulation with viral antigens (6, 36, 37) . The role of IFNy produced by dengue-specific T lymphocytes is another important subject to be further elucidated. IFNy has potent immunoregulatory functions (38, 39) . IFNy increases Fcy receptors on human monocytes (40, 41) . Human monocytes have been identified as cells that support dengue virus infections (42) . It has been reported that anti-dengue antibodies at subneutralizing concentrations augment dengue virus infection ofhuman monocytes, secondary to the increased uptake by monocytes of dengue virus in the form ofdengue virus-antibody complexes via Fc receptors (3). We recently reported that recombinant human IFNy augments dengue virus infection of human monocytes and the human monocytic cell line U937 in the presence of anti-dengue antibody, and that the augmented dengue virus infection is due to the augmented expression of Fc receptors induced by IFN (5) . In these experiments, we showed that dengue virusspecific CD4+ T cells produce high levels of IFNy in response to dengue antigens and that culture fluids which contain IFNy produced by dengue-specific T cells augment dengue virus infection of human monocytes in the presence of anti-dengue antibody. T cell sensitization and IFN7y production would occur during primary dengue infections, and the restimulation of primed cross-reactive T cells, production of IFNy and the presence of virus-antibody complexes in the early phases of secondary dengue infections suggest a model for the pathogenesis of DHF/DSS. Based on these observations, we hypothesize that: IFNy is produced by dengue-specific T lymphocytes after stimulation by dengue virus antigens, and the produced IFNy might contribute to the pathogenesis of DHF and DSS because IFNy increases Fcy receptors on human monocytes and this increases the number of dengue virus-infected monocytes in the presence of anti-dengue antibodies during secondary dengue infections, and by activating macrophages to release vasoactive compounds.
